Clinical Trial Update: Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating re-treatment with Lutetium-177–PSMA in men with metastatic castration-resistant prostate cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• [177Lu]Lu-PSMA (Lutetium-177 labeled PSMA-targeted radioligand therapy)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING